CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...

Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored ...

Pasithea Therapeutics Corp. ( KTTA) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 4:00 PM EST ...

Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, ...

Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference that the company is focused on improving survival in first-line ...

Specifically, the CHMP has backed conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for children ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a ...

Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer ...

Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen’s strong ...